K

Karyopharm Therapeutics
D

KPTI

4.58000
USD
-0.06
(-1.29%)
مغلق
حجم التداول
1,010
الربح لكل سهم
-13
العائد الربحي
-
P/E
-0
حجم السوق
39,570,760
أصول ذات صلة
BMY
BMY
-0.140
(-0.30%)
46.870 USD
B
BPMC
1.130
(1.13%)
101.510 USD
GILD
GILD
0.670
(0.63%)
107.390 USD
INCY
INCY
-0.250
(-0.39%)
64.250 USD
MRK
MRK
-0.220
(-0.28%)
77.600 USD
NVS
NVS
0.240
(0.21%)
112.750 USD
PFE
PFE
0.110
(0.47%)
23.330 USD
Z
ZYME
0.070
(0.61%)
11.550 USD
المزيد
الأخبار المقالات

العنوان: Karyopharm Therapeutics Inc.

القطاع: Healthcare
الصناعة: Biotechnology
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuselarge B-cell lymphoma. The company derives its revenue from United States.